We recently compiled a list of the These 10 Firms Dominated Last Week’s Rally. In this article, we are going to take a look ...

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. D. Boral Capital ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

We recently compiled a list of the 10 Firms Shine Amid Wall Street’s Lackluster Trading. In this article, we are going to ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

ImmunityBio (IBRX) stock was up 15% Thursday, the day after it issued updates on its regulatory submissions in the United ...

Investing.com -- ImmunityBio, an immunotherapy company, saw its shares surge by up to 20%, marking the most significant intraday rise since October 28.

The acquisition's total consideration is $200 million in cash and Symbotic will pay Walmartup to $350 million in additional contingent consideration in future periods dependent upon the quantity of ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its ...

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are ...